Innovative Therapeutics ReNetX Bio specializes in CNS regenerative therapies with their lead product AXER-204, offering a unique approach to neurorepair that could appeal to pharmaceutical companies and biotech firms focused on neurological conditions and regenerative medicine.
Early-Stage Growth With recent funding of 2.8 million dollars and approaching Phase 2 clinical trials, ReNetX Bio presents opportunities for partners interested in supporting or investing in promising early-stage neuroscience therapeutics.
Leadership Recognition The company's CEO Erika Smith has received recognition for entrepreneurial innovation which enhances its credibility and visibility, potentially attracting collaborators seeking innovative biotech ventures.
Research Collaborations Having appointed notable scientific advisors and achieved recognition as an innovator, ReNetX Bio is well-positioned to foster research collaborations or secure strategic partnerships within the biotechnology and clinical research sectors.
Market Niche Operating in a specialized niche of CNS injury treatment with a focus on neural regeneration, ReNetX Bio presents targeted opportunities for investors and partners interested in neurotechnology, CNS disorders, and biotech innovation markets.
$100M$250M
$25M$50M
$250M$500M
$1M$10M
$250M$500M
$1M$10M
$1M
$10M$25M
$1MReNetX Bio uses 8 technology products and services including Snowplow, Weebly, Google Fonts API, and more. Explore ReNetX Bio's tech stack below.
| ReNetX Bio Email Formats | Percentage |
| FLast@renetx.com | 50% |
| FLast@renetx.com | 50% |
Biotechnology ResearchConnecticut, United States2-10 Employees
Our mission is to provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), glaucoma, and traumatic brain injury. Our treatment, AXER-204, hopes to rebuild connections between healthy and damaged neurons through the blocking of receptors that naturally inhibit axonal growth. We are currently approaching Phase 2 of testing.
Company Overview
Funding & FinancialsReNetX Bio has raised a total of $2.8M of funding over 3 rounds. Their latest funding round was raised on Sep 28, 2020 in the amount of $2.8M.
ReNetX Bio's revenue is estimated to be in the range of $1M
Funding & FinancialsReNetX Bio has raised a total of $2.8M of funding over 3 rounds. Their latest funding round was raised on Sep 28, 2020 in the amount of $2.8M.
ReNetX Bio's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com